The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics
Authors:
- Yang Gyu ChoiYCYang Gyu Choi
- Sohee SonSSSohee Son
- Sung Youb JungSJSung Youb Jung
- Doo Sung LeeDLDoo Sung Lee
- Kang Choon LeeKLKang Choon Lee
- 1 May 2010
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 144 (1) , 10-16
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Science and Technology (2009-0081871)
- National Research Foundation of Korea
This publication has 28 references indexed in Scilit:
- Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogsJournal of Controlled Release, 2010
- Preparation and Structural, Biochemical, and Pharmaceutical Characterizations of Bile Acid-Modified Long-Acting Exendin-4 DerivativesJournal of Medicinal Chemistry, 2009
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllersJournal of Pharmaceutical Sciences, 2009
- A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db miceJournal of Controlled Release, 2009
- Preparation, Characterization, and Application of Biotinylated and Biotin−PEGylated Glucagon-Like Peptide-1 Analogues for Enhanced Oral DeliveryBioconjugate Chemistry, 2007
- Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 DiabetesDiabetes Care, 2007
- The role of gut hormones in glucose homeostasisJournal of Clinical Investigation, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- A model for receptor–peptide binding at the glucagon‐like peptide‐1 (GLP‐1) receptor through the analysis of truncated ligands and receptorsBritish Journal of Pharmacology, 2003